The DOI matches its Crossref record; 14 of the 16 references it cites were found in a registry or an index.
Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease
Abstract
The safety and tolerability of high dosages of coenzyme Q10 were studied in 17 patients with Parkinson's disease (PD) in an open label study. The subjects received an escalating dosage of coenzyme Q10--1200, 1800, 2400, and 3000 mg/day with a stable dosage of vitamin E (alpha-tocopherol) 1200 IU/day. The plasma level of coenzyme Q10 was measured at each dosage. Thirteen of the subjects achieved the maximal dosage, and adverse events were typically considered to be unrelated to coenzyme Q10. The plasma level reached a plateau at the 2400 mg/day dosage and did not increase further at the 3000 mg/day dosage. Our data suggest that in future studies of coenzyme Q10 in PD, a dosage of 2400 mg/day (with vitamin E/alpha-tocopherol 1200 IU/day) is an appropriate highest dosage to be studied.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, plasma CoQ10 levels reached a plateau at the 2400 mg/day dosage and did not increase further at the 3000 mg/day dosage in PD, HD or ALS patients161, 162.”
From Mitochondrial Approaches for Neuroprotection (2008) · cites this paper as [161]
Citations
Cites
Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline
Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984
Self-citationStocker, R., Bowry, V. W., & Frei, B. B. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.5.1646 · Cited by 797
Mohr, D., Bowry, V. W., & Stocker, R. (1992) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(92)90237-p · Cited by 313
Biomedical and clinical aspects of coenzyme Q
Littarru, G. P. (1993) · Journal of Molecular Medicine · doi:10.1007/bf00184478 · Cited by 310
Lass, A., & Sohal, R. S. (1998) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1997.0606 · Cited by 162
Lass, A., & Sohal, R. S. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.1.87 · Cited by 128
Bioavailability of four oral Coenzyme Q10 formulations in healthy volunteers
Weis, M., Mortensen, S. A., Rassing, M. R., Sonnergaard, J. M., Poulsen, G., & Rasmussen, S. N. (1994) · Molecular Aspects of Medicine · doi:10.1016/0098-2997(94)90038-8 · Cited by 102
Kontush, A., Hübner, C., Finckh, B., Kohlschütter, A., & Beisiegel†, U. (1995) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(95)00115-s · Cited by 75
Pharmacokinetic study of deuterium-labelled coenzyme Q10 in man.
Tomono, Y., Hasegawa, J., Seki, T., Motegi, K., & Morishita, N. (1986) · PubMed · Cited by 73
Interactions between ubiquinones and vitamins in membranes and cells
Constantinescu, A., Maguire, J. J., & Packer, L. (1994) · Molecular Aspects of Medicine · doi:10.1016/0098-2997(94)90013-2 · Cited by 73
Cited by
Sorted by citations
Items 201–222 of 222
Developing a neuroprotective therapy for Parkinson’s and Huntington’s diseases
Kazantsev, A. G. (2007) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.17.2.159
KATERE SO PRILAGODITVENE REAKCIJE NA TELESNO
Eiken, O. (2008)
Coenzyme Q10 and Behavior in Huntington’s Disease
Hickey, M. A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407824-6.00091-4
Hassanshahi, J., Zamani, M. M., Soleimani, M., & Zamani, F. (2013) · Zahedan Journal of Research in Medical Sciences
Koenzym Q10 beim Morbus Parkinson : Symptomatische oder neuroprotektive Effekte?
Storch, A. (2007) · Der Nervenarzt
The cutting edge: apoptosis and therapeutic opportunity
Griffin, C., Gueorguieva, D., McLachlan-Burgess, A., Somayajulu‐Nitu, M., & Pandey, S. (2007) · Elsevier eBooks · doi:10.1533/9781845693077.2.117
Industrial Production of Nanonutraceuticals
Rajendran, K., & Sen, S. (2016) · Nutraceuticals · doi:10.1201/9781315370859-15
Natural Neuroprotectives for the Management of Parkinson's Disease
Gaba, B., Kumar, S., Md, S., Baboota, S., Narang, J. K., & Ali, J. (2017) · Wiley eBooks · doi:10.1002/9783527803781.ch4
Research Priorities for Complementary Medicine in Australia
Bensoussan, A. (2013)
Experimental Models and New, Emerging Therapies for Parkinson Disease
Fahn, S., Jankovic, J. J., Hallett, M., & Jenner, P. G. (2007) · Elsevier eBooks · doi:10.1016/b978-0-443-07941-2.50012-7
Nyariki, J. N., & Isaac, A. O. (2019) · Parasitology International · doi:10.1016/j.parint.2019.101970
Roxas, R. C. D., & Jamora, R. D. G. (2017) · Acta Medica Philippina · doi:10.47895/amp.v51i2.595
Kachko, R., & LoGiudice, P. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-43044-9.00205-3
(2006) · CRC Press eBooks · doi:10.1201/b14623-16
Mischley, L. K., Jennings, K., Bongiorno, P. B., & LoGiudice, P. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4377-2333-5.00196-6
(2015) · Elsevier eBooks · doi:10.1016/b978-3-437-31618-0.16001-8
Mushtaq, F., Ali, H., Rauf, S. E., Qamar, A., Ali, A. S., Khalid, R., & Shoaib, A. (2023) · European Journal of Anatomy · doi:10.52083/iwcu1147
Tomar, M., Dwivedi, S., & Darwhekar, G. (2025) · Premier Journal of Biomedical Science · doi:10.70389/pjs.100185
Effects of coenzyme Q10 on retinal inflammation in streptozotocin-induced diabetic rats
Akdoğan, M., Karaca, Ç., & Demirel, H. H. (2026) · BMC Ophthalmology · doi:10.1186/s12886-026-04863-0
Lu, H., Ning, X., He, Q., 雷千蕴, Hu, P., & Liang, Y. (2026) · Food Bioscience · doi:10.1016/j.fbio.2026.109494
He, F., Wang, R., Xu, Y., Chen, Y., Xiang, F., Wang, Z., Yang, C., Xiao, W., Wu, Y., Luo, M., et al. (2026) · Metabolism and Diseases · doi:10.1016/j.metdis.2026.100025
Drug-induced mitochondrial impairment: Mechanisms and testing systems
Heidari, R., Ommati, M. M., & Niknahad, H. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-45078-5.00008-7
Metadata
- Authors
- Shults, C. W., Flint Beal, M., Song, D., & Fontaine, D.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Shults, Clifford W.
- ORCID
- Song, David
- Venue
- Experimental Neurology
- Publisher
- Elsevier BV
- Published
- 2004-08
- Volume
- 188
- Issue
- 2
- Pages
- 491-494
- ISSN
- 0014-4886 (ISSN-L)
- OpenAlex
- W1990908870
- Cited by
- 223
- References
- 16
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 1 · 2023: 8 · 2022: 8 · 2021: 10 · 2020: 8 · 2019: 6 · 2018: 6 · 2017: 7 · 2016: 9 · 2015: 7 · 2014: 13 · 2013: 13 · 2012: 13
- FWCI
- 5.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Experimental Neurology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Keywords
- coenzyme Q10, Parkinson's disease, high-dose supplementation, vitamin E, alpha-tocopherol, safety and tolerability, dose escalation, adverse events
- MeSH terms
- Calcium, Coenzymes, Cognition, Dose-Response Relationship, Drug, Drug Therapy, Combination, Dyspepsia, Female, Humans, Male, Middle Aged, Motor Activity, Parkinson Disease, Pilot Projects, Safety, Time Factors, Ubiquinone, Vitamin E
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
